Androgen Receptor Expression Predicts Beneficial Tamoxifen Response in Oestrogen Receptor-α-negative Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2016 Jan 8

PMID 26742006

Citations 31

Authors

Erik Hilborn

Jelena Gacic

Tommy Fornander

Bo Nordenskjold

Olle Stal

Agneta Jansson

Affiliations

Soon will be listed here.

Abstract

Background: Although the androgen receptor (AR) is frequently expressed in breast cancer, its relevance in the disease is not fully understood. In addition, the relevance of AR in determining tamoxifen treatment efficiency requires evaluation.

Purpose: To investigate the tamoxifen predictive relevance of the AR protein expression in breast cancer.

Methods: Patients were randomised to tamoxifen 40 mg daily for 2 or 5 years or to no endocrine treatment. Mean follow-up was 15 years. Hazard ratios were calculated with recurrence-free survival as end point.

Results: In patients with oestrogen receptor (ER)-negative tumours, expression of AR predicted decreased recurrence rate with tamoxifen (hazard ratio (HR)=0.34; 95% confidence interval (CI)=0.14-0.81; P=0.015), whereas the opposite was seen in the AR- group (HR=2.92; 95% CI=1.16-7.31; P=0.022). Interaction test was significant P<0.001. Patients with triple-negative and AR+ tumours benefitted from tamoxifen treatment (HR=0.12; 95% CI=0.014-0.95 P=0.044), whereas patients with AR- tumours had worse outcome when treated with tamoxifen (HR=3.98; 95% CI=1.32-12.03; P=0.014). Interaction test was significant P=0.003. Patients with ER+ tumours showed benefit from tamoxifen treatment regardless of AR expression.

Conclusions: AR can predict tamoxifen treatment benefit in patients with ER- tumours and triple-negative breast cancer.

Citing Articles

Prevalence of Androgen Receptor in Invasive Breast Cancer and Its Association with Clinicopathologic Features in East Azarbaijan Province of Iran: A Cross-Sectional Study.

Nikanfar A, Nikanfar M, Fakhrjou A Int J Hematol Oncol Stem Cell Res. 2023; 17(3):186-193.

PMID: 37817975 PMC: 10560644. DOI: 10.18502/ijhoscr.v17i3.13308.

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type.

Subhan M, Parveen F, Shah H, Yalamarty S, Ataide J, Torchilin V Cancers (Basel). 2023; 15(8).

PMID: 37190133 PMC: 10137302. DOI: 10.3390/cancers15082204.

A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer.

Kumar H, Gupta N, Jain R, Madhunapantula S, Babu C, Kesharwani S J Adv Res. 2023; 54:271-292.

PMID: 36791960 PMC: 10703733. DOI: 10.1016/j.jare.2023.02.005.

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.

Sgroi D, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I Breast Cancer Res. 2022; 24(1):90.

PMID: 36527133 PMC: 9758861. DOI: 10.1186/s13058-022-01589-x.

Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: a single institution study.

Sridhar N, Glisch C, Jawa Z, Chaudhary L, Kamaraju S, Burfeind J J Cancer. 2022; 13(8):2472-2476.

PMID: 35711833 PMC: 9174868. DOI: 10.7150/jca.67536.

References

Luo X, Shi Y, Li Z, Jiang W . Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010; 29(6):585-90. DOI: 10.5732/cjc.009.10673. View

Elebro K, Butt S, Dorkhan M, Jernstrom H, Borgquist S . Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. Cancer Causes Control. 2014; 25(8):945-57. DOI: 10.1007/s10552-014-0394-2. View

Lin F, Pincerato K, Bacchi C, Baracat E, Carvalho F . Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity. J Clin Pathol. 2011; 65(1):64-8. DOI: 10.1136/jclinpath-2011-200318. View

Qu Q, Mao Y, Fei X, Shen K . The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One. 2013; 8(12):e82650. PMC: 3853592. DOI: 10.1371/journal.pone.0082650. View

Castellano I, Allia E, Accortanzo V, Vandone A, Chiusa L, Arisio R . Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010; 124(3):607-17. DOI: 10.1007/s10549-010-0761-y. View

Vera-Badillo F, Templeton A, de Gouveia P, Diaz-Padilla I, Bedard P, Al-Mubarak M . Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2013; 106(1):djt319. DOI: 10.1093/jnci/djt319. View

Tokunaga E, Hisamatsu Y, Taketani K, Yamashita N, Akiyoshi S, Okada S . Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer. Cancer Med. 2014; 2(6):763-73. PMC: 3892381. DOI: 10.1002/cam4.138. View

Rutqvist L, Johansson H . Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007; 46(2):133-45. DOI: 10.1080/02841860601034834. View

Peters A, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera M, Harris J . Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009; 69(15):6131-40. DOI: 10.1158/0008-5472.CAN-09-0452. View

10.

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

11.

Bhattacharyya R, Krishnan A, Swami S, Feldman D . Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther. 2006; 5(6):1539-49. DOI: 10.1158/1535-7163.MCT-06-0065. View

12.

Choi J, Kang S, Lee S, Bae Y . Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol. 2014; 22(1):82-9. DOI: 10.1245/s10434-014-3984-z. View

13.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

14.

Birrell S, Bentel J, Hickey T, Ricciardelli C, Weger M, Horsfall D . Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995; 52(5):459-67. DOI: 10.1016/0960-0760(95)00005-k. View

15.

Park S, Park H, Koo J, Yang W, Kim S, Park B . Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res Treat. 2012; 133(1):311-20. DOI: 10.1007/s10549-011-1950-z. View

16.

Chia K, OBrien M, Brown M, Lim E . Targeting the androgen receptor in breast cancer. Curr Oncol Rep. 2015; 17(2):4. DOI: 10.1007/s11912-014-0427-8. View

17.

. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351(9114):1451-67. View

18.

De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I . Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2009; 121(1):1-11. PMC: 2995248. DOI: 10.1007/s10549-009-0436-8. View

19.

McGhan L, McCullough A, Protheroe C, Dueck A, Lee J, Nunez-Nateras R . Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol. 2013; 21(2):361-7. DOI: 10.1245/s10434-013-3260-7. View

20.

Ni M, Chen Y, Lim E, Wimberly H, Bailey S, Imai Y . Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011; 20(1):119-31. PMC: 3180861. DOI: 10.1016/j.ccr.2011.05.026. View